Eledon Pharmaceuticals Inc (ELDN) - Net Assets
Based on the latest financial reports, Eledon Pharmaceuticals Inc (ELDN) has net assets worth $136.78 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($237.60 Million) and total liabilities ($100.82 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ELDN financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $136.78 Million |
| % of Total Assets | 57.57% |
| Annual Growth Rate | N/A |
| 5-Year Change | -16.6% |
| 10-Year Change | 409.27% |
| Growth Volatility | 556.31 |
Eledon Pharmaceuticals Inc - Net Assets Trend (2012–2025)
This chart illustrates how Eledon Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore Eledon Pharmaceuticals Inc (ELDN) total assets for the complete picture of this company's asset base.
Annual Net Assets for Eledon Pharmaceuticals Inc (2012–2025)
The table below shows the annual net assets of Eledon Pharmaceuticals Inc from 2012 to 2025. For live valuation and market cap data, see ELDN company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $136.78 Million | +15.78% |
| 2024-12-31 | $118.14 Million | +41.62% |
| 2023-12-31 | $83.42 Million | -0.91% |
| 2022-12-31 | $84.18 Million | -48.67% |
| 2021-12-31 | $164.00 Million | -13.96% |
| 2020-12-31 | $190.60 Million | +1913.69% |
| 2019-12-31 | $9.46 Million | -34.69% |
| 2018-12-31 | $14.49 Million | -25.50% |
| 2017-12-31 | $19.45 Million | -27.57% |
| 2016-12-31 | $26.86 Million | -56.49% |
| 2015-12-31 | $61.72 Million | -40.36% |
| 2014-12-31 | $103.50 Million | +287.27% |
| 2013-12-31 | $-55.27 Million | -38.51% |
| 2012-12-31 | $-39.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Eledon Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35387300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $75.00K | 0.05% |
| Other Comprehensive Income | $24.00K | 0.02% |
| Other Components | $537.88 Million | 393.25% |
| Total Equity | $136.78 Million | 100.00% |
Eledon Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Eledon Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Indomobil Sukses Internasional
JK:IMAS
|
$249.26 Million |
|
Pacific Smiles Group Ltd
AU:PSQ
|
$249.29 Million |
|
Ernst Russ AG
XETRA:ERAG
|
$249.30 Million |
|
Grupa Azoty Zaklady Chemiczne Police SA
WAR:PCE
|
$249.48 Million |
|
Akfen Gayrimenkul Yatirim Ortakligi AS
IS:AKFGY
|
$248.95 Million |
|
Bharat Rasayan Limited
NSE:BHARATRAS
|
$248.90 Million |
|
Multilaser Industrial SA
SA:MLAS3
|
$248.73 Million |
|
HPL Electric & Power Limited
NSE:HPL
|
$248.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Eledon Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 118,140,000 to 136,779,000, a change of 18,639,000 (15.8%).
- Net loss of 45,617,000 reduced equity.
- New share issuances of 53,577,000 increased equity.
- Other comprehensive income decreased equity by 2,000.
- Other factors increased equity by 10,681,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-45.62 Million | -33.35% |
| Share Issuances | $53.58 Million | +39.17% |
| Other Comprehensive Income | $-2.00K | -0.0% |
| Other Changes | $10.68 Million | +7.81% |
| Total Change | $- | 15.78% |
Book Value vs Market Value Analysis
This analysis compares Eledon Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.21x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-420.88 | $3.69 | x |
| 2013-12-31 | $-582.96 | $3.69 | x |
| 2014-12-31 | $2591.80 | $3.69 | x |
| 2015-12-31 | $444.72 | $3.69 | x |
| 2016-12-31 | $1263.13 | $3.69 | x |
| 2017-12-31 | $74.85 | $3.69 | x |
| 2018-12-31 | $28.97 | $3.69 | x |
| 2019-12-31 | $14.44 | $3.69 | x |
| 2020-12-31 | $131.32 | $3.69 | x |
| 2021-12-31 | $11.07 | $3.69 | x |
| 2022-12-31 | $5.89 | $3.69 | x |
| 2023-12-31 | $3.39 | $3.69 | x |
| 2024-12-31 | $2.43 | $3.69 | x |
| 2025-12-31 | $1.67 | $3.69 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Eledon Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -33.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.74x
- Recent ROE (-33.35%) is above the historical average (-58.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.66 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.20 Million |
| 2014 | -22.51% | 0.00% | 0.00x | 1.04x | $-33.65 Million |
| 2015 | -73.05% | 0.00% | 0.00x | 1.10x | $-51.26 Million |
| 2016 | -141.33% | 0.00% | 0.00x | 1.11x | $-40.64 Million |
| 2017 | -67.43% | 0.00% | 0.00x | 1.07x | $-15.06 Million |
| 2018 | -97.05% | 0.00% | 0.00x | 1.17x | $-15.51 Million |
| 2019 | -169.16% | 0.00% | 0.00x | 1.15x | $-16.96 Million |
| 2020 | -11.97% | -19009.17% | 0.00x | 1.03x | $-41.87 Million |
| 2021 | -21.04% | -28755.00% | 0.00x | 1.04x | $-50.91 Million |
| 2022 | -104.49% | 0.00% | 0.00x | 1.10x | $-96.38 Million |
| 2023 | -48.34% | 0.00% | 0.00x | 1.51x | $-48.67 Million |
| 2024 | -30.63% | 0.00% | 0.00x | 1.50x | $-48.00 Million |
| 2025 | -33.35% | 0.00% | 0.00x | 1.74x | $-59.29 Million |
Industry Comparison
This section compares Eledon Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Eledon Pharmaceuticals Inc (ELDN) | $136.78 Million | 0.00% | 0.74x | $249.24 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for C… Read more